Guide

What to consider when building a channel strategy for a rare disease product

A checklist for biopharma companies

Evaluating channel strategy options for a rare disease product is an essential element of commercialization. Biopharma companies should ask themselves these five questions to ensure their novel therapy reaches the right patients at the right time.

Enter your information below to download the checklist. 

Pardot Form

Related resources

White paper

Evolving landscape of payer coverage for cell and gene therapies (CGTs): Trends and insights

Webinar

Regulatory Data Initiatives in the EU – What you need to know for 2026

Webinar

Harnessing AI to revolutionize pharmacovigilance signal management